What is m6A modification? N6-methyladenosine (m6A) is the most common internal chemical modification found on messenger RNA molecules in human cells. It acts like a molecular tag that controls how long an mRNA survives and how efficiently it is translated into protein.
The YTHDF2 protein is a 'reader' of m6A tags - it binds marked mRNAs and accelerates their degradation. When YTHDF2 levels are low, m6A-tagged mRNAs accumulate and drive abnormal gene expression patterns that can promote cancer.
The core finding of this study is that YTHDF2 is significantly reduced in human hepatocellular carcinoma (HCC), the most common form of liver cancer. This reduction allows harmful inflammatory and vessel-disrupting mRNAs to persist and drive tumor progression.
Clinical relevance was established by showing that low YTHDF2 expression predicts poor prognosis in HCC patients, making it both a potential biomarker and a therapeutic target.
Transcriptome-wide m6A profiling was performed using m6A-specific immunoprecipitation combined with high-throughput sequencing (MeRIP-seq). This technique pulls down all mRNAs carrying m6A marks and identifies them by their sequence.
Mass spectrometry validation used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure global m6A levels in HCC versus normal liver tissue, providing a quantitative confirmation of the sequencing results.
Patient tumor samples from HCC patients were compared with matched adjacent non-tumor liver tissue, allowing the researchers to directly measure how the m6A landscape changes during cancer formation.
Functional studies used YTHDF2 silencing in human HCC cell lines and genetic ablation in mouse hepatocytes to determine what happens when this protein is removed, mimicking the low-YTHDF2 state found in tumors.
Global m6A gain in HCC was observed: human HCC showed significantly higher overall m6A modification levels compared to normal liver, yet paradoxically this was accompanied by higher - not lower - mRNA expression of m6A-marked transcripts, because YTHDF2 was absent to degrade them.
IL11 and SERPINE2 as key targets were identified as the primary downstream effectors. Both encode secreted proteins: IL11 is an inflammatory cytokine that activates immune signaling, while SERPINE2 (also called protease nexin-1) disrupts normal blood vessel architecture around tumors.
Tumor vasculature abnormalization was directly demonstrated - when YTHDF2 was absent, blood vessels within and around tumors became structurally abnormal (disorganized, leaky), a state that promotes tumor survival and impairs drug delivery.
Metastatic progression was enhanced in mouse models lacking YTHDF2 in hepatocytes, confirming that the protein suppresses not just primary tumor growth but also the spread of cancer cells to other organs.
Hypoxia drives the loss of YTHDF2 - tumors frequently have low oxygen regions, and the researchers found that hypoxia-inducible factor-2alpha (HIF-2alpha) directly suppresses the transcription of the YTHDF2 gene. This creates a cascade where tumor hypoxia reduces YTHDF2, which then allows IL11 and SERPINE2 to accumulate.
A feedback loop was identified: low oxygen activates HIF-2alpha, which turns off YTHDF2, which allows inflammatory mRNAs to persist, which worsens the tumor microenvironment, creating even more hypoxia.
PT2385, a HIF-2alpha antagonist, was tested as a way to break this loop. By blocking HIF-2alpha, the drug restored YTHDF2 expression, which then re-established normal m6A mRNA decay of IL11 and SERPINE2.
Therapeutic proof-of-concept was demonstrated: PT2385 treatment in HCC mouse models repressed liver cancer growth, validating the HIF-2alpha - YTHDF2 axis as a druggable pathway.
Prognostic value in HCC patients was established by correlating YTHDF2 expression levels with patient survival data. Low YTHDF2 consistently predicted shorter overall survival and earlier recurrence after surgical resection.
Biomarker potential is significant because YTHDF2 levels can be measured in tumor biopsy specimens using standard immunohistochemistry, making clinical implementation feasible without requiring expensive genetic testing.
Drug target opportunity exists because the HIF-2alpha - YTHDF2 - IL11/SERPINE2 axis represents a linear pathway with multiple intervention points. PT2385, already in clinical trials for kidney cancer, could potentially be repurposed for HCC.
Combination therapy rationale emerges from this work - restoring YTHDF2 function could sensitize HCC tumors to anti-inflammatory treatments or anti-angiogenic drugs already approved for liver cancer such as sorafenib.
Beyond IL11 and SERPINE2 - the m6A transcriptome analysis identified many other mRNAs that accumulate when YTHDF2 is lost. Future work is needed to determine which of these additional targets also contribute to HCC progression.
Other m6A readers such as YTHDF1 and YTHDF3 also exist and their roles in HCC remain to be fully characterized. Understanding how the entire m6A reader network is disrupted in liver cancer may reveal additional therapeutic targets.
Liquid biopsy development is a priority - whether m6A modification changes or YTHDF2 levels can be detected in circulating tumor DNA or exosomes would make this biomarker accessible without requiring tumor biopsy.
Clinical translation of PT2385 to HCC patients requires dedicated clinical trials, since the drug has only been tested in kidney cancer to date. Biomarker-stratified trials selecting patients with low YTHDF2 HCC would be the logical first step.